Please assess the completion status of the following clinical trial:

Trial Title: Effects of Denosumab on the Pharmacokinetics of Etanercept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women (postmenopausal is defined as no vaginal bleeding or spotting for at least 12 months)~* Low bone mineral density (BMD) as determined by screening BMD T-scores of the lumbar spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip ≤ -1.0~* Receiving a 50 mg dose of etanercept once weekly ≥ 6 months prior to screening and expected to continue etanercept treatment at this dose and frequency through end of study (EOS)~* If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week) of MTX ≥ 8 weeks prior to screening~* Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily upon enrollment~Exclusion Criteria:~* Type 1 diabetes; OR poorly controlled Type 2 diabetes (hemoglobin A1c (HbA1c) \> 8.0% at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting laboratory documentation is available)~* History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR history of acute coronary syndrome~* Comorbid autoimmune disease, demyelinating disease, or hematologic abnormalities~* History of joint replacement in hand and/or wrist; OR history of fused joint in hand and/or wrist~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR active dental or jaw condition that requires oral surgery, or non-healed dental/oral surgery; OR planned invasive dental procedure(s) during the course of the study~* Previous exposure to denosumab

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept + Denosumab (Type: EXPERIMENTAL): Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).